Domainex Collaborates with St George’s University and The University of Manchester for Asthma Treatment
News Jul 10, 2009
Domainex Ltd, St George’s University of London, and The University of Manchester have announced that they are collaborating on a new drug discovery programme to provide a better treatment for asthma.
Domainex will provide lead optimization services for an asthma research programme being undertaken at St George’s. The total contract value for Domainex exceeds £1.5 million in research fees over two years.
Scientists led by Clive Robinson, Professor in Respiratory Cell Science at St George’s, working in collaboration with Professor David Garrod at Manchester and a team from Domainex, have discovered drug-like compounds that inhibit Der p1, an enzyme that triggers asthma attacks. St George’s University of London and The University of Manchester have recently been awarded a £4 million research grant from the Wellcome Trust's Seeding Drug Discovery Initiative to take this research programme forward.
Domainex will apply its LeadBuilder technology - which uses virtual screening capability to select chemical compounds suitable for rapid progression - and its medicinal chemistry expertise to assist the St George’s team to develop a drug candidate to take into clinical trials.
Eddy Littler, Chief Executive Officer of Domainex, said: “This collaboration with St George’s University of London and The University of Manchester demonstrates Domainex’s core expertise in computational and medicinal chemistry. It is also a testament to our commitment to the support of translational research in academia. The combination of LeadBuilder and our medicinal chemistry expertise creates a powerful drug discovery tool.”
Professor Clive Robinson said: “The innovative services provided by Domainex’s scientists, together with the support of the Wellcome Trust, will help us to accelerate the development of our exciting anti-asthma compounds.”
Professor David Garrod said: “This is a most exciting development in a productive on-going collaboration that promises to bring real benefit to the millions who suffer from respiratory allergies.”
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE
Researchers report that an experimental drug called vosoritide, allowed the average annual growth rate to increase in a study of 35 children and teenagers with a form of dwarfism. The average boost in height per year was ~6 centimeters (2.4 inches) which is close to growth rates among children of average stature.READ MORE